Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib resistance mechanism and potential ways to conquer
Wentao Bo, Yan Chen
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12

Showing 12 citing articles:

Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System
Haiqing Wang, Wentao Bo, Xielin Feng, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5581-5603
Open Access | Times Cited: 3
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Tal Sigawi, Ram Gelman, Ofra Maimon, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Solanum torvum induces ferroptosis to suppress hepatocellular carcinoma
Hsiang-Chun Lai, Jui‐Chun Weng, Huichi Huang, et al.
Journal of Ethnopharmacology (2024) Vol. 335, pp. 118670-118670
Closed Access | Times Cited: 2
Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic MEN1 Mutation
Y Ito, Toshinori Imaizumi, Hisashi Daido, et al.
JCEM Case Reports (2024) Vol. 2, Iss. 8
Open Access | Times Cited: 1
Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC
Yijie Zhang, Lei Jin, Huaxing Ma, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1507-1517
Open Access | Times Cited: 1
Role of APE1 in hepatocellular carcinoma and its prospects as a target in clinical settings (Review)
Lei Yang, Zhipeng Sun
Molecular and Clinical Oncology (2024) Vol. 21, Iss. 5
Open Access
New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer
Jungmin Kim, Hang‐Seok Chang, Hyeok Jun Yun, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10646-10646
Open Access
Hepatitis B Virus-Induced Resistance to Sorafenib and Lenvatinib in Hepatocellular Carcinoma Cells: Implications for Cell Viability and Signaling Pathways
Narmen Esmael, Ido Lubin, Ran Tur‐Kaspa, et al.
Cancers (2024) Vol. 16, Iss. 22, pp. 3763-3763
Open Access
Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma
Nan Yi, Lingyun Zhang, Xiangbo Huang, et al.
Cellular Oncology (2024)
Open Access
GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation
Peihong Zhang, Shiping Chen, Jia-Liang Cai, et al.
Cellular Oncology (2024)
Closed Access
Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer
Ben Ma, Youzhou Sang, Xiaoxue Du, et al.
Advanced Science (2024)
Open Access
Page 1

Scroll to top